On January 29, the Federal Trade Commission (FTC) published increased reporting thresholds under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). The new thresholds increase last year’s thresholds by approximately 4%. The revised thresholds are effective for all transactions closing on or after February 28, 2018. The revised thresholds will remain in effect until the FTC’s next annual adjustment, which should be released during the first quarter of 2019.
The HSR Act requires parties to mergers, acquisitions, joint ventures, and certain ...
Annually, the Federal Trade Commission (FTC) is required to revise the basic thresholds used to determine reportability of transactions under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), based on the change in our gross national product. Once again the thresholds have increased. The changes were effective February 27, 2017.
Most importantly, the minimum “size of transaction” threshold is increased to $80.8 million from $78.2 million last year. Accordingly, an acquisition, merger, or joint venture where at least $80.8 million of assets ...
The Internet, like so many things in life, is not free. The content we consume must be paid for and that usually means viewing advertisements. But as our software and browsers become increasingly adept at blocking pop-ups and banner ads, advertisers have found themselves going native. “Native advertising” refers to paid advertisements that are designed to look like a publisher’s own editorial content. Native advertising is attractive to both the publishers and the advertisers. Native ads frequently command a hefty premium over traditional ads (a boon to the publisher) and ...
On January 17, 2013, the Federal Trade Commission (FTC) issued a report revealing an increase in “pay-for-delay” or “reverse-payment” patent settlements between brand-name pharmaceutical companies and their generic counterparts
These controversial settlements typically involve a brand-name drug manufacturer who is granted a drug patent which gives the company the exclusive right to sell the drug for up to 20 years, depending on the type of drug. The patent is then challenged by a generic rival. Rather than risk losing their patent monopoly on account of a judgment ...
Not so fast. Rachel is Robocaller associated with unwanted calls to consumers by multiple “Cardholder Services” companies offering credit card interest rate reductions in exchange for an up-front fee.
The Federal Trade Commission is not amused. On November 1, 2012 the FTC announced successful prosecution of five companies based in Arizona and Florida responsible for millions of illegal pre-recorded calls from Rachel. Federal courts granted the FTC’s request for temporary restraining orders to halt the operations of the companies. FTC Chairman Leibowitz commented ...